Get startedLog in
    Picture of Valbiotis SA logo

    ALVAL — Valbiotis SA News Story

    0.000.00%
    fr flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: Valbiotis' TOTUM-854 To Enter Clinical Development Phase In 2021

    Picture of Valbiotis SA logoValbiotis SA
    08/03/2021 17:21
    March 8 (Reuters) - VALBIOTIS SA  ALVAL.PA :
    * TOTUM-854 TO BE THIRD ACTIVE SUBSTANCE IN VALBIOTIS
PIPELINE TO
ENTER CLINICAL DEVELOPMENT PHASE, IN 2021

Source text for Eikon:  ID:nBw94sqG6a 
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00 ;))

    Recent news on Valbiotis SA

    See all news